<DOC>
	<DOCNO>NCT00409188</DOCNO>
	<brief_summary>The purpose study determine whether cancer vaccine tecemotide ( L-BLP25 ) addition best supportive care effective prolonging life subject unresectable stage III non-small cell lung cancer , compare best supportive care alone . A local ancillary ( sub ) study European center evaluate immune response peripheral blood tecemotide ( L-BLP25 ) placebo vaccination .</brief_summary>
	<brief_title>Cancer Vaccine Study Unresectable Stage III Non-small Cell Lung Cancer ( START )</brief_title>
	<detailed_description>Ancillary Trial : An exploratory investigation immune response peripheral blood tecemotide ( L-BLP25 ) placebo vaccination . The ancillary study sub-study within START . This exploratory investigation immune response peripheral blood tecemotide ( L-BLP25 ) placebo vaccination . The main objective evaluate whether administration single-shot , low-dose cyclophosphamide follow tecemotide ( L-BLP25 ) vaccination induces specific immune response peripheral blood BLP25 ( mucinous glycoprotein 1 [ MUC1 ] antigen ) well modulation cellular soluble component immune response subject unresectable stage III NSCLC . Twenty-five European START sit participate ancillary study . Sample size : 60 80 subject All inclusion criterion specify START clinical trial protocol except hemoglobin &gt; = 100 gram/Liter ( g/L ) All exclusion criterion specify START clinical trial protocol Schedule event : Blood sample take baseline , visit week 4 , 8 13 25 ( 80 milliliter ( mL ) whole blood )</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<criteria>Histologically cytologically document unresectable stage III nonsmall cell lung cancer ( NSCLC ) Documented stable disease objective response , accord Response Evaluation Criteria Solid Tumors ( RECIST ) , primary chemoradiotherapy ( either sequential concomitant ) unresectable stage III disease , within 4 week ( 28 day ) prior randomization Receipt concomitant sequential chemoradiotherapy , consist minimum two cycle platinumbased chemotherapy minimum radiation dose &gt; =50 Gray ( Gy ) . Subjects must complete primary thoracic chemoradiotherapy least four week ( 28 day ) later 12 week ( 84 day ) prior randomization . Subjects receive prophylactic brain irradiation part primary chemoradiotherapy eligible Geographically accessible ongoing followup , commit comply designate visit An Eastern Cooperative Oncology Group ( ECOG ) performance status 01 A platelet count &gt; 140 x 10^9/Liter ; white blood cell ( WBC ) &gt; 2.5 x 10^9/Liter hemoglobin &gt; 90 gram per liter ( g/L ) PreTherapies : Undergone lung cancer specific therapy ( include surgery ) primary chemoradiotherapy Receipt immunotherapy ( e.g . interferon , tumor necrosis factor [ TNF ] , interleukins , biological response modifier [ granulocyte macrophage colony stimulate factor { GMCSF } , granulocyte colony stimulate factor { GCSF } , macrophagecolony stimulate factor { MCSF } ] , monoclonal antibody ) within 4 week ( 28 day ) prior randomization Receipt investigational systemic drug ( include offlabel use approve product ) within 4 week ( 28 day ) prior randomization Disease Status : Metastatic disease Malignant pleural effusion initial diagnosis and/or study entry Past current history neoplasm lung carcinoma , except curatively treat nonmelanoma skin cancer , situ carcinoma cervix cancer curatively treat evidence disease least 5 year Autoimmune disease A recognized immunodeficiency disease include cellular immunodeficiency , hypogammaglobulinemia dysgammaglobulinemia ; subject hereditary congenital immunodeficiency Any preexist medical condition require chronic steroid immunosuppressive therapy ( steroids treatment radiation pneumonitis allow ) Known Hepatitis B and/or C Physiological Functions : Clinically significant hepatic dysfunction Clinically significant renal dysfunction Clinically significant cardiac disease Splenectomy Infectious process opinion investigator could compromise subject 's ability mount immune response Standard Safety : Pregnant breastfeed woman , woman childbearing potential , unless use effective contraception determine investigator Known drug abuse/alcohol abuse Legal incapacity limit legal capacity</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Non-Small Cell Lung Carcinoma ;</keyword>
	<keyword>stage III ;</keyword>
	<keyword>unresectable ;</keyword>
	<keyword>vaccine ; Tecemotide ; L-BLP25 ;</keyword>
	<keyword>Cyclophosphamide ;</keyword>
	<keyword>placebo control ;</keyword>
	<keyword>randomize ;</keyword>
	<keyword>double blind ;</keyword>
	<keyword>immunotherapy ;</keyword>
</DOC>